Search
forLearn
5 / 801 resultsResearch
5 / 16 results
research Application of mesenchymal stem cells derived from bone marrow and umbilical cord in human hair multiplication
Bone marrow and umbilical cord stem cells can help grow new hair.
research Hair growth promoting effect of dermal papilla like tissues from canine adipose-derived mesenchymal stem cells through vascular endothelial growth factor
Lab-made tissues from dog fat stem cells can help grow hair by releasing a growth factor.
research Optimization of the reconstruction of dermal papilla like tissues employing umbilical cord mesenchymal stem cells
Using umbilical cord stem cells can help create hair-growing tissues more affordably.
research Canine Adipose-Derived Stem Cell Aggregates as a Viable Substitute to Actual Canine Dermal Papillae
Canine stem cell aggregates can effectively replace natural dermal papillae for hair research.
research Hair multiplication with dermal papilla like tissue containing human dermal papilla cells
Injecting lab-grown hair cells into the scalp can regrow hair.
Community Join
5 / 1000+ resultscommunity Post Low-Level Laser Light Therapy Syndrome (PLLLTS )
Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community How much do we know about PTD-DBM?
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.